Details of the Drug

General Information of Drug (ID: DMWT905)

Drug Name
Mefloquine
Synonyms
Lariam; Mefloquin; Mefloquina; Mefloquinone; Mefloquinum; Mephloquine; Racemic mefloquine; Ro 215998; WR 142490; Lariam (Hydrochloride); Lariam (TN); Mefaquin (TN); Mefloquina [INN-Spanish]; Mefloquinum [INN-Latin]; RO 13-7224; RO 13-7225; Ro 21-5998; SPB-80406; WR-142490; Mefloquine (USAN/INN); Mefloquine [USAN:INN:BAN]; RTI1169-1-1; RTI1172-1-1; RTI1173-1-1; RTI1174-1-1; RTI1188-1-1; RTI1189-1-1; Ro 21-5998 (Hydrochloride); WR-142,490; WR-177,602; Ro-21-5998-001; Alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; (+)-(11R,2'S)-erythro-Mefloquine; (+)-Mefloquine; (+)-Threo-Mefloquine; (-)-(11S,2'R)-erythro-Mefloquine; (-)-Mefloquine; (-)-Threo-Mefloquine; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol
Indication
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [2]
Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [3]
Severe acute respiratory syndrome (SARS) 1D65 Preclinical [3]
Progressive multifocal leukoencephalopathy 8A45.02 Investigative [4]
Therapeutic Class
Antimalarials
Affected Organisms
Plasmodium falciparum
ATC Code
P01BC02: Mefloquine
P01BC: Methanolquinolines
P01B: ANTIMALARIALS
P01: ANTIPROTOZOALS
P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 378.31
Logarithm of the Partition Coefficient (xlogp) 3.6
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability
80% of drug becomes completely available to its intended biological destination(s) [6]
Elimination
9% of drug is excreted from urine in the unchanged form [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 47.2012 micromolar/kg/day [7]
Chemical Identifiers
Formula
C17H16F6N2O
IUPAC Name
[2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol
Canonical SMILES
C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
InChI
InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2
InChIKey
XEEQGYMUWCZPDN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4046
ChEBI ID
CHEBI:63681
CAS Number
49752-90-1
UNII
TML814419R
DrugBank ID
DB00358
TTD ID
D0GQ7K
VARIDT ID
DR00623
INTEDE ID
DR1016
ACDINA ID
D00391
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasmodium 80S ribosome (Malaria 80S) TTT28H3 NOUNIPROTAC Binder [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mefloquine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Mefloquine and Lumefantrine. Malaria [1F40-1F45] [11]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Mefloquine and Halofantrine. Malaria [1F40-1F45] [12]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Mefloquine and Hydroxychloroquine. Malaria [1F40-1F45] [13]
Coadministration of a Drug Treating the Disease Different from Mefloquine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Mefloquine and Ivosidenib. Acute myeloid leukaemia [2A60] [14]
Arn-509 DMT81LZ Moderate Increased metabolism of Mefloquine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Gilteritinib. Acute myeloid leukaemia [2A60] [16]
Mitotane DMU1GX0 Moderate Increased metabolism of Mefloquine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [15]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Mefloquine and Metronidazole. Amoebiasis [1A36] [11]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Mefloquine and Ivabradine. Angina pectoris [BA40] [17]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Mefloquine and Bepridil. Angina pectoris [BA40] [18]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Mefloquine and Dronedarone. Angina pectoris [BA40] [18]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Mefloquine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [19]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Levalbuterol. Asthma [CA23] [20]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Terbutaline. Asthma [CA23] [21]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Mefloquine and Pirbuterol. Asthma [CA23] [21]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Mefloquine and Salbutamol. Asthma [CA23] [20]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Mefloquine and Formoterol. Asthma [CA23] [21]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [17]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Ofloxacin. Bacterial infection [1A00-1C4Z] [22]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Mefloquine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [18]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Mefloquine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [22]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [22]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Norfloxacin. Bacterial infection [1A00-1C4Z] [22]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Levofloxacin. Bacterial infection [1A00-1C4Z] [22]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Mefloquine caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [15]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Loperamide. Bowel habit change [ME05] [23]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Eribulin. Breast cancer [2C60-2C6Y] [18]
Tucatinib DMBESUA Moderate Decreased metabolism of Mefloquine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Mefloquine and Toremifene. Breast cancer [2C60-2C6Y] [18]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Bosutinib. Breast cancer [2C60-2C6Y] [17]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Mefloquine and Grepafloxacin. Bronchitis [CA20] [22]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Mefloquine and Sotalol. Cardiac arrhythmia [BC9Z] [18]
Secobarbital DM14RF5 Moderate Increased metabolism of Mefloquine caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [15]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [25]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Mefloquine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [21]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Mefloquine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [20]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [21]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Mefloquine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [21]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [21]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Mefloquine caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [15]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Isoproterenol. Conduction disorder [BC63] [20]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Propofol. Corneal disease [9A76-9A78] [26]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Sevoflurane. Corneal disease [9A76-9A78] [18]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Clofazimine. Crohn disease [DD70] [27]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Mefloquine and Mifepristone. Cushing syndrome [5A70] [18]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Mefloquine and Pasireotide. Cushing syndrome [5A70] [18]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Osilodrostat. Cushing syndrome [5A70] [17]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Mefloquine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [28]
MK-8228 DMOB58Q Moderate Decreased metabolism of Mefloquine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [29]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Mefloquine and Escitalopram. Depression [6A70-6A7Z] [18]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Trazodone. Depression [6A70-6A7Z] [30]
Mirtazapine DML53ZJ Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Mirtazapine. Depression [6A70-6A7Z] [31]
Griseofulvin DMK54YG Moderate Increased metabolism of Mefloquine caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [15]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [18]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Deutetrabenazine. Dystonic disorder [8A02] [32]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Ingrezza. Dystonic disorder [8A02] [33]
Cenobamate DM8KLU9 Moderate Increased metabolism of Mefloquine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Stiripentol DMMSDOY Moderate Decreased metabolism of Mefloquine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [34]
Tazemetostat DMWP1BH Moderate Increased metabolism of Mefloquine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [15]
Ketoconazole DMPZI3Q Major Decreased metabolism of Mefloquine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [15]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Mefloquine and Cisapride. Gastro-oesophageal reflux disease [DA22] [18]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Mefloquine caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [15]
Rifampin DMA8J1G Moderate Increased metabolism of Mefloquine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [15]
Rifapentine DMCHV4I Moderate Increased metabolism of Mefloquine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [15]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [35]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Mefloquine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [36]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Mefloquine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [37]
Etravirine DMGV8QU Moderate Increased metabolism of Mefloquine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [18]
Darunavir DMN3GCH Moderate Decreased metabolism of Mefloquine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Conivaptan DM1V329 Moderate Decreased metabolism of Mefloquine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [39]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Mefloquine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [40]
Amobarbital DM0GQ8N Moderate Increased metabolism of Mefloquine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [15]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Mefloquine and Polyethylene glycol. Irritable bowel syndrome [DD91] [18]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Mefloquine and Phenolphthalein. Irritable bowel syndrome [DD91] [18]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Mefloquine and Crizotinib. Lung cancer [2C25] [41]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Mefloquine and Ceritinib. Lung cancer [2C25] [18]
PF-06463922 DMKM7EW Moderate Increased metabolism of Mefloquine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [15]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Mefloquine and Osimertinib. Lung cancer [2C25] [42]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Mefloquine and Selpercatinib. Lung cancer [2C25] [17]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [17]
Idelalisib DM602WT Moderate Decreased metabolism of Mefloquine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [43]
IPI-145 DMWA24P Moderate Decreased metabolism of Mefloquine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [44]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Mefloquine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [45]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Mefloquine and Vemurafenib. Melanoma [2C30] [18]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and LGX818. Melanoma [2C30] [46]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Mefloquine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [15]
Propranolol DM79NTF Moderate Increased risk of bradycardia by the combination of Mefloquine and Propranolol. Migraine [8A80] [15]
Exjade DMHPRWG Moderate Decreased metabolism of Mefloquine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [47]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Mefloquine and Panobinostat. Multiple myeloma [2A83] [48]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Mefloquine and Thalidomide. Multiple myeloma [2A83] [11]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Mefloquine and Siponimod. Multiple sclerosis [8A40] [11]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Mefloquine and Fingolimod. Multiple sclerosis [8A40] [18]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Mefloquine and Ozanimod. Multiple sclerosis [8A40] [49]
Rifabutin DM1YBHK Moderate Increased metabolism of Mefloquine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [15]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Mefloquine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [17]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Mefloquine and Nilotinib. Myeloproliferative neoplasm [2A20] [18]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Mefloquine and Droperidol. Nausea/vomiting [MD90] [18]
Metoclopramide DMFA5MY Minor Altered absorption of Mefloquine due to GI dynamics variation caused by Metoclopramide. Nausea/vomiting [MD90] [50]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Mefloquine and Dolasetron. Nausea/vomiting [MD90] [51]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Mefloquine and Bupropion. Nicotine use disorder [6C4A] [52]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Entrectinib. Non-small cell lung cancer [2C25] [11]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Mefloquine and Levomethadyl Acetate. Opioid use disorder [6C43] [17]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Pimavanserin. Parkinsonism [8A00] [53]
Abametapir DM2RX0I Moderate Decreased metabolism of Mefloquine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [54]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Mefloquine and Lindane. Pediculosis [1G00] [55]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Famotidine. Peptic ulcer [DA61] [11]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Mefloquine and Macimorelin. Pituitary gland disorder [5A60-5A61] [56]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Mefloquine and Lefamulin. Pneumonia [CA40] [57]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Mefloquine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [58]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Ritodrine. Preterm labour/delivery [JB00] [21]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Degarelix. Prostate cancer [2C82] [17]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Mefloquine and ABIRATERONE. Prostate cancer [2C82] [17]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Nilutamide. Prostate cancer [2C82] [17]
Enzalutamide DMGL19D Moderate Increased metabolism of Mefloquine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [15]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Flutamide. Prostate cancer [2C82] [17]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Relugolix. Prostate cancer [2C82] [17]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Bicalutamide. Prostate cancer [2C82] [17]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Mefloquine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [59]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Sorafenib. Renal cell carcinoma [2C90] [18]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Mefloquine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [60]
Dexamethasone DMMWZET Moderate Increased metabolism of Mefloquine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [15]
Nafcillin DMN9RPO Moderate Increased metabolism of Mefloquine caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [15]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Quetiapine. Schizophrenia [6A20] [18]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Mefloquine and Mesoridazine. Schizophrenia [6A20] [18]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Mefloquine and Thioridazine. Schizophrenia [6A20] [18]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Mefloquine and Iloperidone. Schizophrenia [6A20] [18]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Mefloquine and Haloperidol. Schizophrenia [6A20] [18]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Mefloquine and Clozapine. Schizophrenia [6A20] [18]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Mefloquine and Amisulpride. Schizophrenia [6A20] [61]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Asenapine. Schizophrenia [6A20] [18]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Mefloquine and Pimozide. Schizophrenia [6A20] [17]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Mefloquine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [17]
Larotrectinib DM26CQR Moderate Decreased metabolism of Mefloquine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [11]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Mefloquine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [18]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [17]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Mefloquine and Pitolisant. Somnolence [MG42] [17]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Mefloquine and Adenosine. Supraventricular tachyarrhythmia [BC81] [18]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Mefloquine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [62]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Mefloquine and Cabozantinib. Thyroid cancer [2D10] [17]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Mefloquine and Papaverine. Tonus and reflex abnormality [MB47] [63]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Mefloquine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [59]
Elagolix DMB2C0E Moderate Increased metabolism of Mefloquine caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [15]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Mefloquine and Procainamide. Ventricular tachyarrhythmia [BC71] [18]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Mefloquine and Amiodarone. Ventricular tachyarrhythmia [BC71] [18]
⏷ Show the Full List of 142 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Calcium alginate E00576 44630049 Disintegrant; Emulsifying agent; Modified-release agent; Viscosity-controlling agent
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Mefloquine 250 mg tablet 250 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 019578
2 ClinicalTrials.gov (NCT04347031) An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19. U.S. National Institutes of Health.
3 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
4 Mefloquine FDA Label
5 BDDCS applied to over 900 drugs
6 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 An ultrastructural study of the effects of mefloquine on malaria parasites. Am J Trop Med Hyg. 1987 Jan;36(1):9-14.
9 Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
10 Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol. 2000 Oct;52(10):1265-9.
11 Cerner Multum, Inc. "Australian Product Information.".
12 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
13 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
14 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
15 Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
16 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Canadian Pharmacists Association.
19 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
20 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
21 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
22 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
23 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
24 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
25 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
26 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
27 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
28 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
29 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
30 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
31 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
32 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
33 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
34 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
35 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
36 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
37 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
38 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
39 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
40 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
41 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
44 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
45 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
46 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
47 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
48 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
49 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
50 Bangchang KN, Karbwang J, Bunnag D, et al "The effect of metoclopramide on mefloquine pharmacokinetics." Br J Clin Pharmacol 32 (1991): 640-1. [PMID: 1954082]
51 Product Information. Anzemet (dolasetron). Hoechst Marion-Roussel Inc, Kansas City, MO.
52 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
53 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
54 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
55 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
56 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
57 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
58 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
59 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
60 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
61 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
62 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
63 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]